Fangqiu Fu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/378646/publications.pdf Version: 2024-02-01



ΕλΝΟΟΙΙΙ ΕΠ

#	Article	IF	CITATIONS
1	The prognostic value of Kirsten rat sarcoma viral oncogene homolog mutations in resected lung adenocarcinoma differs according to clinical features. Journal of Thoracic and Cardiovascular Surgery, 2022, 163, e73-e85.	0.8	18
2	Subsolid Lesions Exceeding 3 Centimeters: The Ground-Glass Opacity Component Still Matters. Annals of Thoracic Surgery, 2022, 113, 984-992.	1.3	5
3	Subsolid Lung Adenocarcinomas: Radiological, ClinicalÂand Pathological Features and Outcomes. Seminars in Thoracic and Cardiovascular Surgery, 2022, 34, 702-710.	0.6	11
4	Decreasing Prevalence of Benign Etiology in Resected Lung Nodules Suspicious for Lung Cancer over the Last Decade. Seminars in Thoracic and Cardiovascular Surgery, 2022, 34, 1093-1099.	0.6	6
5	Clinical, pathological and radiologic features of minute pulmonary meningothelial-like nodules. Journal of Cancer Research and Clinical Oncology, 2022, 148, 1473-1479.	2.5	2
6	Overuse of follow-up chest computed tomography in patients with incidentally identified nodules suspicious for lung cancer. Journal of Cancer Research and Clinical Oncology, 2022, 148, 1147-1152.	2.5	1
7	Emerging High-Risk Population of Lung Cancer: To Reveal the Unrevealed. Journal of Thoracic Oncology, 2022, 17, e18-e20.	1.1	1
8	Pregnancy may have little influence on ground-glass opacities suspected for lung adenocarcinoma. Journal of Cancer Research and Clinical Oncology, 2022, , 1.	2.5	0
9	Prognostic value of epidermal growth factor receptor gene mutation in resected lung adenocarcinoma. Journal of Thoracic and Cardiovascular Surgery, 2021, 162, 664-674.e7.	0.8	34
10	Computed tomography density is not associated with pathological tumor invasion for pure ground-glass nodules. Journal of Thoracic and Cardiovascular Surgery, 2021, 162, 451-459.e3.	0.8	21
11	Gefitinib as neoadjuvant therapy for resectable stage II-IIIA non–small cell lung cancer: A phase II study. Journal of Thoracic and Cardiovascular Surgery, 2021, 161, 434-442.e2.	0.8	58
12	Excellent Prognosis of Patients With Invasive Lung Adenocarcinomas During Surgery Misdiagnosed as Atypical Adenomatous Hyperplasia, Adenocarcinoma In Situ, or Minimally Invasive Adenocarcinoma by Frozen Section. Chest, 2021, 159, 1265-1272.	0.8	16
13	Lung cancer screening strategy for non-high-risk individuals: a narrative review. Translational Lung Cancer Research, 2021, 10, 452-461.	2.8	8
14	Combination of CD47 and CD68 expression predicts survival in eastern-Asian patients with non-small cell lung cancer. Journal of Cancer Research and Clinical Oncology, 2021, 147, 739-747.	2.5	8
15	Primary Tumor Resection Improves Survival for EGFR-TKI-Treated Patients With Occult M1a Lung Adenocarcinoma. Frontiers in Oncology, 2021, 11, 622723.	2.8	2
16	The Prognostic Value of Preoperative Serum Tumor Markers in Non-Small Cell Lung Cancer Varies With Radiological Features and Histological Types. Frontiers in Oncology, 2021, 11, 645159.	2.8	10
17	Genetic-pathological prediction for timing and site-specific recurrence pattern in resected lung adenocarcinoma. European Journal of Cardio-thoracic Surgery, 2021, 60, 1223-1231.	1.4	6
18	Systemic immune-inflammation index is a stage-dependent prognostic factor in patients with operable non-small cell lung cancer. Translational Lung Cancer Research, 2021, 10, 3144-3154.	2.8	15

Fangqiu Fu

#	Article	IF	CITATIONS
19	Impact of Adjuvant Therapy on Survival in Surgically Resected Limited-Stage Small Cell Lung Cancer. Frontiers in Oncology, 2021, 11, 704517.	2.8	1
20	Clinicopathologic features and prognostic value of epidermal growth factor receptor mutation in patients with pT1a and pT1b invasive lung adenocarcinoma after surgical resection. Journal of Thoracic Disease, 2021, 13, 5496-5507.	1.4	2
21	Validation of the Novel International Association for the Study of Lung Cancer Grading System for Invasive Pulmonary Adenocarcinoma and Association With Common Driver Mutations. Journal of Thoracic Oncology, 2021, 16, 1684-1693.	1.1	54
22	Segment Location and Ground Glass Opacity Ratio Reliably Predict Node-Negative Status in Lung Cancer. Annals of Thoracic Surgery, 2020, 109, 1061-1068.	1.3	32
23	EGFR-mutant lung adenocarcinoma harboring co-mutational tumor suppressor genes predicts poor prognosis. Journal of Cancer Research and Clinical Oncology, 2020, 146, 1781-1789.	2.5	13
24	Management of Ground-Glass Opacities in the Lung Cancer Spectrum. Annals of Thoracic Surgery, 2020, 110, 1796-1804.	1.3	98
25	Development and validation of a fiveâ€gene model to predict postoperative brain metastasis in operable lung adenocarcinoma. International Journal of Cancer, 2020, 147, 584-592.	5.1	23
26	Comparison of outcomes following segmentectomy or lobectomy for patients with clinical N0 invasive lung adenocarcinoma of 2Acm or less in diameter. Journal of Cancer Research and Clinical Oncology, 2020, 146, 1603-1613.	2.5	12
27	Ground-glass opacity-featured lung adenocarcinoma has no response to chemotherapy. Journal of Cancer Research and Clinical Oncology, 2020, 146, 2411-2417.	2.5	5
28	Distinct Prognostic Factors in Patients with Stage lÂNon–Small Cell Lung Cancer with Radiologic Part-Solid or Solid Lesions. Journal of Thoracic Oncology, 2019, 14, 2133-2142.	1.1	120
29	A prognostic score system with lymph node ratio in stage IIIA-N2 NSCLC patients after surgery and adjuvant chemotherapy. Journal of Cancer Research and Clinical Oncology, 2019, 145, 2115-2122.	2.5	9
30	Androgenâ€responsive lncRNA LINC00304 promotes cell cycle and proliferation via regulating CCNA1. Prostate, 2019, 79, 994-1006.	2.3	13
31	Lung Adenocarcinomas Manifesting as Radiological Part-Solid Nodules Define a Special Clinical Subtype. Journal of Thoracic Oncology, 2019, 14, 617-627.	1.1	151
32	SNORA42 enhances prostate cancer cell viability, migration and EMT and is correlated with prostate cancer poor prognosis. International Journal of Biochemistry and Cell Biology, 2018, 102, 138-150.	2.8	41
33	MicroRNA-19a acts as a prognostic marker and promotes prostate cancer progression via inhibiting VPS37A expression. Oncotarget, 2018, 9, 1931-1943.	1.8	20
34	Co-expression analysis revealed PTCH1-3'UTR promoted cell migration and invasion by activating miR-101-3p/SLC39A6 axis in non-small cell lung cancer: implicating the novel function of PTCH1. Oncotarget, 2018, 9, 4798-4813.	1.8	21
35	An androgen reduced transcript of LncRNA GAS5 promoted prostate cancer proliferation. PLoS ONE, 2017, 12, e0182305.	2.5	41
36	Identification of androgen-responsive IncRNAs as diagnostic and prognostic markers for prostate cancer. Oncotarget, 2016, 7, 60503-60518.	1.8	83